-
-
Doctors tend to prescribe less tamoxifen to the oldest-old and also to those with significant comorbidities (in both age groups) or those unmarried and without living children. With increasing life expectancy currently being observed in these age groups, this study raises the possibility that oncologists may be missing the opportunity to help the oldest breast cancer patients achieve therapeutic benefit from tamoxifen.
-
Outcomes following resection of pancreas cancer have improved recently, more than can be accounted for by a drop in procedure-related mortality. This study from the Harvard School of Public Health performed a retrospective analysis of claims-based Medicare data and correlated it with SEER data to identify prognostic factors that may be contributing to this phenomenon.
-
-
-
In a 5-year retrospective analysis of lung cancer in Asian immigrants living in Boston and seen at the New England Medical Center, more-advanced disease and shorter survival was observed when compared to non-Asian, and age- and gender-matched controls.
-
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) is still considered the gold standard in first-line therapy for aggressive non-Hodgkins lymphoma. Despite its place in clinical practice for 3 decades, there are issues that still are being evaluated.
-
The clinical value of single-agent trastuzumab in recurrent ovarian cancer is limited by the low frequency of HER2 overexpression and low rate of objective response among patients with HER2 overexpression.
-
Given that fewer than half of families approached about organ donation give consent, it is essential that hospitals and procurement coordinators examine how they approach families at such a crucial time, say officials with the United Network for Organ Sharing (UNOS).
-
UT Supreme Court upholds wrongful-life statute; Consumer group claims doctors strike unlawful; NEJM retracts study after authors point to forgery
